The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: xylitol canada inc.

Monday Deal Review: December 2, 2013

  Welcome to your Monday Biotech Deal Review for December 2, 2013! Hit the break to see this week’s major biotech news.

Read more of this post

Monday Deal Review: September 23, 2013

  Welcome to your Monday Biotech Deal Review for September 23, 2013! Now that we are in the full swing of September, the activity in the market has ramped up.

In terms of M&A, Axxess has purchased the assets of Revive Bioscience, including Revive’s product and IP portfolios, for an undisclosed amount. Easton has re-entered the drug market by purchasing rights in a female sexual arousal disorder drug. And MTPC has completed its acquisition of Medicago. Medicago’s shares are no longer listed as a result.

In terms of financing, IMRIS and Xylitol have both enetered into loan agreements. However, a number of other companies are also rasing capital through placements, including MedMira, Miraculins, and Bioniche .

Theres lots more to report, so hit the break to see the past weeks’ major biotech stories.

Once again, a big thank you to Jennifer Ng for her help in getting these stories to you.

Read more of this post

Monday Deal Review: January 14, 2013

Welcome to your Monday Biotech Deal Review for January 14, 2013! This week’s big news is that Cytochroma, a privately held company, will be acquired by OPKO Health.  Also on the M&A side, Asia-Biochem completed their acquisition of China’s Tieling Wanshunda Starch Company Ltd for over CDN$44 million. There was not much activity in the investment space, however ProMetric has been able to close $10 million in financing from Shenzhen Hepalink Pharmaceutical Co.,  as we’ve covered previously.  Find out more about these transactions, as well as the rest of this week’s major Canadian Biotech news, by clicking through! Read more of this post

Monday Deal Review: December 3, 2012

Welcome to your Monday Biotech Deal Review for December 3, 2012.  An unusually high number of private placements characterized the past week’s Canadian biotech activity, with Biosign Technologies having closed one private placement and following up with another. Cynapsus has filed a short form prospectus, following last week’s filing by Allon Therepeutics, and Patheon has indicated they intend to make a cash tender offer for outstanding senior notes.  See more detail on these and last week’s other major biotech stories by clicking through!
Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 130 other followers